NOS2 and bronchopneumonia: A rat model of bronchopneumonia was established by the intranasal injection of lipopolysaccharides (1 mL/g), and it was found that salidroside (30, 60 mg/kg) significantly reduced the number of eosinophils, neutrophils, and lymphocytes in alveolar lavage fluid, and down-regulated the expression of IL-1β, iNOS, and Keap1, while up-regulating the expression of Nrf2 in the lung tissues, suggesting that salidroside may alleviate the inflammatory response of bronchopneumonia by activating the Nrf2/Keap1 signaling pathway [154].